U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07516899) titled 'Mass Balance Study of [14C] LPM3770164 in Healthy Participants' on April 01.
Brief Summary: This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of [14C] LPM3770164.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Huntington Disease
Intervention:
DRUG: [14C] LPM3770164
The subjects are required to take 20 mg/150 µCi [14C] LPM3770164 tablet (s) in the fasted state with a total of approximately 240 mL of water to ensure completion withi...